On 4 March, the Germany-based pharmaceutical company Vivoryon Therapeutics announced results from its Phase 2b study evaluating Varoglutamstat for the treatment of early Alzheimer’s disease (AD). The VIVIAD Phase 2b study was designed to evaluate the safety, tolerability and efficacy of Varoglutamstat in 259 European participants with mild cognitive impairment and mild AD (collectively referred to as “early AD”). Varoglutamstat is an enzyme inhibitor developed to target the enzyme glutaminyl cyclase, which catalyses the formation of a particularly neurotoxic variant of Amyloid-beta (N3pE). Top-line results showed that the VIVIAD Phase 2 study failed to reach its primary endpoint and did not show significant difference in change over time on cognition. Additionally, the study did not meet key secondary clinical endpoints. In general, Varoglutamstat was well-tolerated and showed few adverse events. Vivoryon Therapeutics is conducting further analysis of other (exploratory) cognitive and biomarker endpoints. The full press release can be accessed here: